Kazuaki Chayama, Shoichi Takahashi, Joji Toyota, Yoshiyasu Karino, Kenji Ikeda, Hiroki Ishikawa, Hideaki Watanabe, Fiona McPhee, Eric Hughes, Hiromitsu Kumada – 10 October 2011 – Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg‐IFN) and ribavirin (RBV) have limited therapeutic options. HCV genotype 1 is the most common worldwide and the most difficult to treat; genotype 1b is the most common subtype of genotype 1 outside North America.

Tony Jourdan, Laurent Demizieux, Joseph Gresti, Louiza Djaouti, Lila Gaba, Bruno Vergès, Pascal Degrace – 10 October 2011 – It is well established that inactivation of the central endocannabinoid system (ECS) through antagonism of cannabinoid receptor 1 (CB1R) reduces food intake and improves several pathological features associated with obesity, such as dyslipidemia and liver steatosis. Nevertheless, recent data indicate that inactivation of peripheral CB1R could also be directly involved in the control of lipid metabolism independently of central CB1R.

Chao‐Wei Hsu, Chau‐Ting Yeh – 4 October 2011

Li Sun, Jiu‐Cong Zhang – 3 October 2011

Naim Alkhouri, Gaurav Kistangari, Carla Campbell, Rocio Lopez, Nizar N. Zein, Ariel E. Feldstein – 3 October 2011

Tai‐Chung Tseng, Jia‐Horng Kao – 3 October 2011

30 September 2011

30 September 2011

30 September 2011

Wenhua Liang, Dongping Wang, Xiaoting Ling, Andrew Allen Kao, Yuan Kong, Yushu Shang, Zhiyong Guo, Xiaoshun He – 30 September 2011 – Sirolimus (SRL) is a novel immunosuppressant with antitumor properties. We performed a meta‐analysis to determine whether SRL can improve patient survival and decrease the risks of tumor recurrence in patients with a pretransplant diagnosis of hepatocellular carcinoma (HCC). We searched databases for controlled clinical trials assessing the survival and oncological benefits of SRL for liver transplant recipients with pretransplant HCC.